{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:34:06Z","timestamp":1777584846857,"version":"3.51.4"},"reference-count":16,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,10,4]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>A 53-year-old woman presented with a 25-year history of acne excori\u00e9e and prurigo excori\u00e9e. Her symptoms began in 1988 coinciding with her husband\u2019s death from a brain tumour when she was 27. The pruritus affected her quality of life and disturbed her sleep. She had scarring on her face and body resulting from persistent scratching. The pruritus proved refractory to treatment despite a multi-modal treatment approach including multiple topicals, phototherapy and systemic agents such as isotretinoin, antibiotics, anxiolytic agents and neuromodulators. She was extremely frustrated that various treatments had been ineffective at controlling the itch-scratch cycle. She was commenced on low dose naltrexone (LDN), 3\u2009mg nocte, and she became itch free within a few weeks. She reports that the LDN has had a beneficial impact on her quality of life.<\/jats:p>","DOI":"10.1136\/bcr-2021-243773","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T10:36:36Z","timestamp":1637318196000},"page":"e243773","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Prurigo excori\u00e9e treated with low dose naltrexone"],"prefix":"10.1136","volume":"14","author":[{"given":"Leonard","family":"Timoney","sequence":"first","affiliation":[{"name":"Department of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6693-7483","authenticated-orcid":false,"given":"Christopher B","family":"Bunker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"2025082706525632000_14.11.e243773.1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Purigo nodularis: epidemiology and clinical features","volume":"6","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025082706525632000_14.11.e243773.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2008.06.048"},{"key":"2025082706525632000_14.11.e243773.3","doi-asserted-by":"crossref","DOI":"10.1089\/apc.1995.9.3","article-title":"Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV\/AIDS","volume":"9","author":"Bihari","year":"1995","journal-title":"AIDS Patient Care"},{"key":"2025082706525632000_14.11.e243773.4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025082706525632000_14.11.e243773.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2517-2"},{"key":"2025082706525632000_14.11.e243773.6","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217724791"},{"key":"2025082706525632000_14.11.e243773.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1653-7"},{"key":"2025082706525632000_14.11.e243773.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2004.09.024"},{"key":"2025082706525632000_14.11.e243773.9","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/bjd.18861","article-title":"Improvement of Hailey-Hailey disease with low-dose naltrexone","volume":"182","author":"Jasans-Barcel\u00f3","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025082706525632000_14.11.e243773.10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00404-020-05705-0","article-title":"Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review","volume":"302","author":"Sousa Gomes","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"2025082706525632000_14.11.e243773.11","doi-asserted-by":"crossref","DOI":"10.4103\/idoj.IDOJ_453_18","article-title":"Low-Dose Naltrexone-Induced remission in Hailey-Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine","volume":"10","author":"Sonthalia","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"2025082706525632000_14.11.e243773.12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jdcr.2018.07.002","article-title":"Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone","volume":"4","author":"Kollman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2025082706525632000_14.11.e243773.13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2019.04.024","article-title":"Low-Dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): a case series","volume":"81","author":"Riquelme-Mc Loughlin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025082706525632000_14.11.e243773.14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jamadermatol.2017.5463","article-title":"Variable response to naltrexone in patients with Hailey-Hailey disease","volume":"154","author":"Cao","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025082706525632000_14.11.e243773.15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15457"},{"key":"2025082706525632000_14.11.e243773.16","first-page":"270","article-title":"Compounded low-dose naltrexone for the treatment of Guttate psoriasis: a case report","volume":"22","author":"Muller","year":"2018","journal-title":"Int J Pharm Compd"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:53:02Z","timestamp":1756302782000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,19]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bcr-2021-243773"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243773","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}